Selective photodynamic therapy by targeted verteporfin delivery to experimental choroidal neovascularization mediated by a homing peptide to vascular endothelial growth factor receptor-2

Archives of Ophthalmology

Volumn 122, Issue 7, 2004, Pages 1002-1011

  Renno, Reem Z ^a,c   Terada, Yoshiko ^a   Haddadin, Makhluf J ^b   Michaud, Norman A ^a   Gragoudas, Evangelos S ^a   Miller, Joan W ^a,d  

^a HARVARD MEDICAL SCHOOL   (United States)

^b AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d MASSACHUSETTS EYE AND EAR INFIRMARY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZOPORPHYRIN DERIVATIVE; HOMING RECEPTOR; POLYVINYL ALCOHOL; VASCULOTROPIN RECEPTOR 2; OLIGOPEPTIDE; PHOTOSENSITIZING AGENT; PORPHYRIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOROID; CLINICAL RESEARCH; CONJUGATION; CONTROLLED STUDY; DISEASE MODEL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG SELECTIVITY; DRUG TARGETING; EVALUATION; FLUORESCENCE ANGIOGRAPHY; HISTOPATHOLOGY; ISOLATION PROCEDURE; NONHUMAN; OPHTHALMOSCOPY; PHOTODYNAMIC THERAPY; PHOTOSENSITIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUALITATIVE ANALYSIS; RAT; RETINA; RETINA MACULA AGE RELATED DEGENERATION; STANDARDIZATION; SUBRETINAL NEOVASCULARIZATION; ANIMAL; BROWN NORWAY RAT; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; PHOTOCHEMOTHERAPY; VASCULAR ENDOTHELIUM;

ANIMALS; CHOROIDAL NEOVASCULARIZATION; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; ENDOTHELIUM, VASCULAR; FLUORESCEIN ANGIOGRAPHY; OLIGOPEPTIDES; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PORPHYRINS; RATS; RATS, INBRED BN; RETINA; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 3342998644     PISSN: 00039950     EISSN: None     Source Type: Journal    
DOI: 10.1001/archopht.122.7.1002     Document Type: Article

References (39)

1. Miller J, Schmidt-Erfurth U, Sickenberg M, et al. Photodynamic therapy for choroidal neovascularization due to age-related macular degeneration with verteporfin: results of a single treatment in a phase 1 and 2 study [published correction appears in Arch Ophthalmol. 2000;118:488]. Arch Ophthalmol. 1999;117:1161-1173.
2. Miller J, Schmidt-Erfurth U, Sickenberg M, et al. Photodynamic therapy for choroidal neovascularization due to age-related macular degeneration with verteporfin: results of a single treatment in a phase 1 and 2 study [published correction appears in Arch Ophthalmol. 2000;118:488]. Arch Ophthalmol. 1999;117:1161-1173.
3. Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials: TAP report 1 [published correction appears in Arch Ophthalmol. 2000;118:488]. Arch Ophthalmol. 1999;117:1329-1345.
4. Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials: TAP report 1 [published correction appears in Arch Ophthalmol. 2000;118:488]. Arch Ophthalmol. 1999;117:1329-1345.
5. Bressler N. Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in related age macular degeneration with verteporfin: two-year results of randomized clinical trials: TAP report 2. Arch Ophthalmol. 2001;119:198-207.
6. Sickenberg M, Schmidt-Erfurth U, Miller J, et al. A preliminary study of photodynamic therapy using verteporfin for choroidal neovascularization in pathologic myopia, ocular histoplasmosis syndrome, angioid streaks, and idiopathic causes. Arch Ophthalmol. 2000;118:327-336.
7. Miller J, Walsh A, Kramer M, et al. Photodynamic therapy of experimental choroidal neovascularization using lipoprotein-delivered benzoporphyrin. Arch Ophthalmol. 1995;113:810-818.
8. Kramer M, Miller J, Mihaud N, et al. Liposomal benzoporphyrin derivative verteporfin photodynamic therapy. Ophthalmology. 1996;103:427-438.
9. Husain D, Kramer M, Kenney A, et al. Effects of photodynamic therapy using verteporfin on experimental choroidal neovascularization and normal retina and choroid up to seven weeks after treatment. Invest Ophthalmol Vis Sci. 1999;40:2322-2331.
10. Reinke M, Canakis C, Hussain D, et al. Verteporfin photodynamic therapy (PDT) retreatment of normal retina and choroid in the cynomolgus monkey. Ophthalmology. 1999;106:1915-1923.
11. Renno R, Defori F, Holzer R, Gragoudas E, Miller J. Photodynamic therapy using Lu-Tex induces apoptosis in vitro and shows potentiate action combined with angiostatin in retinal capillary endothelial cells. Invest Ophthalmol Vis Sci. 2000;41:3963-3971.
12. Gauthier D, Husain D, Kim I, et al. Safety and Efficacy of Intravitreal Injection of rhuFab VEGF in Combination With Verteporfin PDT on Experimental Choroidal Neovascularization. Fort Lauderdale, Fla: Association for Research in Vision & Ophthalmology; 2002.
13. Pasqualini R, Ruoslahti E. Organ targeting in vivo using phage display peptide libraries. Nature. 1996;380:364-366.
14. Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science. 1998;279:377-380.
15. Arap WHW, Bernasconi M, Kain R, et al. Targeting the prostate for destruction through a vascular address. Proc Natl Acad Sci U S A. 2002;99:1527-1531.
16. Miller J, Adamis A, Shima D, et al. Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am J Pathol. 1994;145:574-584.
17. Aiello L, Pierce E, Foley E, et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci U S A. 1995;92:10457-10461.
18. McLeod D, Taomoto M, Cao J, Zhu Z, Witte L, Lutty G. Localization of VEGF receptor-2 (KDR/Flk-1) and effects of blocking it in oxygen-induced retinopathy. Invest Ophthalmol Vis Sci. 2002;43:474-482.
19. Tille J, Wood J, Mandriota S, et al. Vascular endothelial growth factor (VEGF) receptor-2 antagonists inhibit VEGF- and basic fibroblast growth factor-induced angiogenesis in vivo and in vitro. J Pharmacol Exp Ther. 2001;299:1073-1085.
20. Krzystolik M, Afshari M, Adamis A, et al. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol. 2002;120:338-346.
21. Kim I, Ryan A, Rohan R, et al. Constitutive expression of VEGF, VEGFR-1, and VEGFR-2 in normal eyes. Invest Ophthalmol Vis Sci. 1999;40:2115-2121.
22. Wada M, Ogata N, Otsuji T, Uyama M. Expression of vascular endothelial growth factor and its receptor (KDR/flk-1) mRNA in experimental choroidal neovascularization. Curr Eye Res. 1999;18:203-213.
23. Binetruy-Tournaire R, Demangel C, Malavaud B, et al. Identification of a peptide blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis. EMBO J. 2000;19:1525-1533.
24. Lange N, Ballini J, Wagnieres G, Bergh HVD. A new drug-screening procedure for photosensitizing agents used in photodynamic therapy for CNV. Invest Ophthalmol Vis Sci. 2001;42:38-46.
25. Steele K, Liu D, Davis N, Deal H, Levy J. The preparation and application of porphyrin-monocalonal antibodies for cancer therapy. In: Dougherty TJ, ed. Photodynamic Therapy: Mechanisms: 19-20 January 1989, Los Angeles, California. Vol 1065. Bellingham, Wash: International Society for Optical Engineering; 1989:73-79.
26. Jiang FN, Jiang S, Liu D, Richter A, Levy JG. Development of technology for linking photosensitizers to a model monoclonal antibody. J Immunol Methods. 1990;134:139-149.
27. Monner D. An assay for growth of mouse bone marrow cells in microtiter liquid culture using the tetrazolium salt MTT, and its application to studies of myeloporesis. Immunol Lett. 1988;19:261-268.
28. Dobi E, Puliafito C, Destro M. A new model of subretinal neovascularization in the pigmented rat. Arch Ophthalmol. 1989;107:264-269.
29. Tobe T, Takahashi K, Ohkuma H, Uyamam M. Experimental choroidal neovascularization in the rat [in Japanese]. Nippon Ganka Gakkai Zasshi. 1994;98:837-845.
30. Zacks D, Ezra E, Terada Y, et al. Verteporin photodynamic therapy in the rat model of choroidal neovascularization: angiographic and histologic characterization. Invest Ophthalmol Vis Sci. 2002;43:2384-2391.
31. Gilpin D. Calculation of a new Meeh constant and experimental determination of burn size. Burns. 1996;22:607-611.
32. Husain D, Miller J, Michaud N, Connolly E, Flotte T, Gragoudas E. Intravenous infusion of liposomal benzoporphyrin derivative for photodynamic therapy of experimental choroidal neovascularization. Arch Ophthalmol. 1996;114:978-985.
33. Murdter TE, Sperker B, Kivisto KT, et al. Enhanced uptake of doxorubicin into bronchial carcinoma: beta-glucuronidase mediates release of doxorubicin from a glucuronide prodrug (HMR 1826) at the tumor site. Cancer Res. 1997;57:2440-2445.
34. Folli S, Westermann P, Braichotte D, et al. Antibody-indocyanin conjugates for immunophotodetection of human squamous cell carcinoma in nude mice. Cancer Res. 1994;54:2643-2649.
35. Vocero-Akbani AM, Heyden NV, Lissy NA, Ratner L, Dowdy SF. Killing HIV-infected cells by transduction with an HIV protease-activated caspase-3 protein. Nat Med. 1999;5:29-33.
36. Schwarze SR, Ho A, Vocero-Akbani A, Dowdy SF. In vivo protein transduction: delivery of a biologically active protein into the mouse. Science. 1999;285:1569-1572.
37. Schwarze SR, Dowdy SF. In vivo protein transduction: intracellular delivery of biologically active proteins, compounds and DNA. Trends Pharmacol Sci. 2000;21:45-48.
38. Lindgren M, Hallbrink M, Prochiantz A, Langel U. Cell-penetrating peptides. Trends Pharmacol Sci. 2000;21:99-103.
39. Tolentino M, Husain D, Theodosiadis P, et al. Angiography of fluoresceinated anti-vascular endothelial growth factor antibody and dextrans in experimental choroidal neovascularization. Arch Ophthalmol. 2000;118:78-84.